- Home
- HOOK vs IGC Comparison
HOOK vs IGC Comparison
Compare HOOK & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOOK
- IGC
- Stock Information
- Founded
- HOOK 2011
- IGC 2005
- Country
- HOOK United States
- IGC United States
- Employees
- HOOK N/A
- IGC N/A
- Industry
- HOOK Biotechnology: Pharmaceutical Preparations
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- HOOK Health Care
- IGC Health Care
- Exchange
- HOOK Nasdaq
- IGC Nasdaq
- Market Cap
- HOOK 24.5M
- IGC 29.4M
- IPO Year
- HOOK 2019
- IGC N/A
- Fundamental
- Price
- HOOK $1.99
- IGC $0.36
- Analyst Decision
- HOOK Buy
- IGC Strong Buy
- Analyst Count
- HOOK 4
- IGC 2
- Target Price
- HOOK $10.67
- IGC $3.75
- AVG Volume (30 Days)
- HOOK 266.1K
- IGC 393.7K
- Earning Date
- HOOK 03-21-2025
- IGC 02-12-2025
- Dividend Yield
- HOOK N/A
- IGC N/A
- EPS Growth
- HOOK N/A
- IGC N/A
- EPS
- HOOK N/A
- IGC N/A
- Revenue
- HOOK $49,999,000.00
- IGC $1,183,000.00
- Revenue This Year
- HOOK $148.80
- IGC N/A
- Revenue Next Year
- HOOK N/A
- IGC $13.38
- P/E Ratio
- HOOK N/A
- IGC N/A
- Revenue Growth
- HOOK 143.30
- IGC N/A
- 52 Week Low
- HOOK $1.72
- IGC $0.27
- 52 Week High
- HOOK $10.50
- IGC $0.91
- Technical
- Relative Strength Index (RSI)
- HOOK 45.83
- IGC 51.08
- Support Level
- HOOK $1.80
- IGC $0.31
- Resistance Level
- HOOK $1.99
- IGC $0.36
- Average True Range (ATR)
- HOOK 0.24
- IGC 0.02
- MACD
- HOOK 0.05
- IGC 0.00
- Stochastic Oscillator
- HOOK 25.35
- IGC 75.00
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.